These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32316711)

  • 41. Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.
    Luo W; Tian P; Wang Y; Xu H; Chen L; Tang C; Shu Y; Zhang S; Wang Z; Zhang J; Zhang L; Jiang L; Liu L; Che G; Guo C; Zhang H; Wang J; Li W
    Int J Cancer; 2018 Oct; 143(7):1696-1705. PubMed ID: 29667179
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion.
    Wu SG; Liu YN; Yu CJ; Yang JC; Shih JY
    Genes Chromosomes Cancer; 2018 Oct; 57(10):513-521. PubMed ID: 30107055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations.
    Leal LF; de Paula FE; De Marchi P; de Souza Viana L; Pinto GDJ; Carlos CD; Berardinelli GN; Miziara JE; da Silva CM; Silva ECA; Pereira R; de Oliveira MA; Scapulatempo-Neto C; Reis RM
    Sci Rep; 2019 Mar; 9(1):3209. PubMed ID: 30824880
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
    Kim JH; Yoon S; Lee DH; Jang SJ; Chun SM; Kim SW
    Cancer Med; 2021 May; 10(10):3197-3204. PubMed ID: 33960703
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
    Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
    J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
    Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
    Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.
    Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Trejo Rosales R; Rojas L; Cruz-Rico G; Nagy R; Cabrera L; Vargas C; Saam J; Barrón F; Arrieta O
    Oncology; 2021; 99(8):539-546. PubMed ID: 33902046
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma.
    Cai L; Wang J; Yan J; Zeng J; Zhu L; Liang J; Pan C; Huang X; Jin J; Xu Y; Wang F; Shao Y; Xu Q; Xia G; Xing M; Xu X; Jiang Y
    Front Oncol; 2020; 10():603671. PubMed ID: 33505917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
    Zhou W; Liu Z; Wang Y; Zhang Y; Qian F; Lu J; Wang H; Gu P; Hu M; Chen Y; Yang Z; Zhao R; Lou Y; Han B; Zhang W
    Cancer Med; 2022 Mar; 11(5):1299-1309. PubMed ID: 35023616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.
    Park S; Shim JH; Lee B; Cho I; Park WY; Kim Y; Lee SH; Choi Y; Han J; Ahn JS; Ahn MJ; Park K; Sun JM
    Lung Cancer; 2019 Aug; 134():7-15. PubMed ID: 31319998
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Biton J; Mansuet-Lupo A; Pécuchet N; Alifano M; Ouakrim H; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Leroy K; Goc J; Wislez M; Germain C; Laurent-Puig P; Dieu-Nosjean MC; Cremer I; Herbst R; Blons H; Damotte D
    Clin Cancer Res; 2018 Nov; 24(22):5710-5723. PubMed ID: 29764856
    [No Abstract]   [Full Text] [Related]  

  • 54. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Gow CH; Hsieh MS; Wu SG; Shih JY
    Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
    Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA
    Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
    Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients.
    Pan Y; Yuan C; Cheng C; Zhang Y; Ma Y; Zheng D; Zheng S; Li Y; Jin Y; Sun Y; Chen H
    Int J Cancer; 2019 Jan; 144(2):290-296. PubMed ID: 30230541
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma.
    Ito M; Miyata Y; Hirano S; Kimura S; Irisuna F; Ikeda K; Kushitani K; Kishi N; Tsutani Y; Takeshima Y; Okada M
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2325-2333. PubMed ID: 31317326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience.
    Dall'Olio FG; Conci N; Rossi G; Fiorentino M; De Giglio A; Grilli G; Altimari A; Gruppioni E; Filippini DM; Di Federico A; Nuvola G; Ardizzoni A
    Lung Cancer; 2020 Nov; 149():5-9. PubMed ID: 32932213
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular Signatures of
    Hsu J; Annunziata JF; Burns E; Bernicker EH; Olsen RJ; Thomas JS
    Clin Pathol; 2022; 15():2632010X221102054. PubMed ID: 35634237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.